Transforming the treatment of
fibro-inflammatory diseases

Developer of first-in-class therapeutics targeting the IL-11 pathway

Our Focus

IL-11 signalling is a fundamentally important driver of fibrogenesis, organ dysfunction and inflammation across human fibrotic diseases.

Enleofen develops innovative, safe and highly effective therapeutics that address today’s biggest healthcare challenges.

Our Strategy

null

Patient-based discovery platform

null

Therapeutic development based on relevant biology

null

Efficacy across disease models and extensive safety studies

null

Strong human genetic data supporting drug safety

null

Extensive patent portfolio

Our Pipeline

Enx108A is a first-in-class human antibody that targets IL-11. Treatment with ENx108A is anti-fibrotic, anti-inflammatory and reverses organ dysfunction across disease models.

Integrated human discovery and efficacy screening pipelines for all our products.

Read More

null

Our Team

null

Latest News